Omnicell (NASDAQ:OMCL) Price Target Lowered to $36.00 at JPMorgan Chase & Co.

Omnicell (NASDAQ:OMCL) had its price target trimmed by JPMorgan Chase & Co. from $44.00 to $36.00 in a report released on Thursday morning,Benzinga reports. The brokerage currently has a neutral rating on the stock.

A number of other research firms also recently issued reports on OMCL. Wells Fargo & Company dropped their target price on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Benchmark reissued a “buy” rating and set a $62.00 target price on shares of Omnicell in a research report on Tuesday, February 4th. StockNews.com raised shares of Omnicell from a “hold” rating to a “buy” rating in a research report on Thursday, March 6th. Finally, Bank of America decreased their price target on Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a report on Monday, January 6th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $51.00.

Omnicell Trading Down 2.7 %

NASDAQ OMCL opened at $33.94 on Thursday. Omnicell has a 12 month low of $25.12 and a 12 month high of $55.75. The company has a 50-day moving average of $39.77 and a 200-day moving average of $42.90. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22. The company has a market cap of $1.59 billion, a P/E ratio of 125.71, a P/E/G ratio of 7.53 and a beta of 0.85.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. As a group, equities analysts predict that Omnicell will post 1.09 earnings per share for the current year.

Hedge Funds Weigh In On Omnicell

Institutional investors and hedge funds have recently bought and sold shares of the stock. Royce & Associates LP purchased a new position in shares of Omnicell during the 3rd quarter valued at approximately $811,000. Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Omnicell by 750.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 294,037 shares of the company’s stock valued at $12,820,000 after buying an additional 259,463 shares during the last quarter. Intech Investment Management LLC purchased a new position in shares of Omnicell during the 3rd quarter valued at approximately $753,000. Charles Schwab Investment Management Inc. boosted its stake in shares of Omnicell by 3.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 594,996 shares of the company’s stock valued at $25,942,000 after buying an additional 22,198 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in shares of Omnicell by 7.7% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 25,272 shares of the company’s stock valued at $1,102,000 after buying an additional 1,813 shares during the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.